News
Video
Author(s):
Key opinion leaders discuss the sequencing of systemic therapy options for patients with advanced HCC.
Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC
Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer
BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy
Tremelimumab Plus Paclitaxel Generates Responses in Refractory Metastatic Urothelial Cancer
2 Commerce Drive
Cranbury, NJ 08512